1. Home
  2. CFND vs GNTA Comparison

CFND vs GNTA Comparison

Compare CFND & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$5.36

Market Cap

36.5M

Sector

N/A

ML Signal

N/A

Logo Genenta Science S.p.A.

GNTA

Genenta Science S.p.A.

HOLD

Current Price

$1.87

Market Cap

39.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
GNTA
Founded
N/A
2014
Country
Italy
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
39.4M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CFND
GNTA
Price
$5.36
$1.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
111.6K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.35
52 Week High
N/A
$10.00

Technical Indicators

Market Signals
Indicator
CFND
GNTA
Relative Strength Index (RSI) N/A 40.49
Support Level N/A $1.80
Resistance Level N/A $2.20
Average True Range (ATR) 0.00 0.24
MACD 0.00 0.04
Stochastic Oscillator 0.00 59.77

Price Performance

Historical Comparison
CFND
GNTA

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About GNTA Genenta Science S.p.A.

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.

Share on Social Networks: